MycoFinder kit successfully completes EP 2.6.7 validation study

Jul 10, 2020

Nissui Pharma Solutions (NPS) has successfully completed an EP validation study in partnership with Confarma, a Solvias group company, specialized in biological analysis. MycoFinder, a mycoplasma gene detection kit, fulfils all requirements for EP 2.6.7. This Real-time PCR assay is compliant in terms of Limit of Detection (LOD), specificity and robustness. In addition, MycoFinder is comparable to compendial methods (cell culture and cell indicator methods).

MycoFinder will be available in Europe from Q3 2020. 

About Solvias
Solvias is a world leader in contract analytical and process research, development and manufacturing. More information about the Solvias group can be found on the following link:


NPS provides innovative solutions for QC/QA and product release of ATMPs and biopharmaceuticals. 

Contact us

Nissui Pharma Solutions
10, rue Mesnil
75116, Paris

Sales :
Technical support :

*Required fields

For any information concerning the protection of personal data, please consult our privacy policy.

Copyright © Nissui Pharmasolutions, All rights reserved - Legal & credits - Terms of sales

Design by B-to-B Design